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Lack of effects between rupatadine 10mg and placebo
on actual driving performance of healthy volunteers
Eric Vuurman1*, Eef Theunissen2, Anita van Oers1, Cees van Leeuwen1 and Jelle Jolles1
1Brain and Behaviour Institute, Faculty of Medicine, Maastricht University, The Netherlands
2Brain and Behaviour Institute, Faculty of Psychology, Maastricht University, The Netherlands
Introduction Rupatadine fumarate is a potent, selective, histamine H1-receptor antagonist and PAF inhibitor with
demonstrated efficacy for the relief of allergic rhinitis. Rupatadine does not easily cross the blood–brain barrier and is
believed to be non-sedating at therapeutic doses. Consequently, rupatadine should show no impairment on car driving.
Objective This study compared the acute effects of rupatadine, relative to placebo and hydroxyzine (as an active control),
on healthy subjects’ driving performance.
Methods Twenty subjects received a single dose of rupatadine 10mg, hydroxyzine 50mg, or placebo in each period of this
randomized, double-blind, three-way crossover study. Two hours postdosing, subjects operated a specially instrumented
vehicle in tests designed to measure their driving ability. Before and after the driving tests ratings of sedation were recorded.
Results There was no significant difference between rupatadine and placebo in the primary outcome variable: standard
deviation of lateral position (SDLP); however, hydroxyzine treatment significantly increased SDLP (p< 0.001 for both
comparisons). Objective (Stanford sleepiness scale) and subjective sedation ratings (Visual Analogue Scales) showed similar
results: subjects reported negative effects after hydroxyzine but not after rupatadine.
Conclusion Rupatadine 10mg is not sedating and does not impair driving performance. Copyright# 2007 John Wiley &
Sons, Ltd.
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INTRODUCTION
Antihistamine therapy is the first choice in treatment
in many allergic conditions with H1 antihistamines
being one of the largest classes of drugs in use in the
world. Besides mediating targeted peripheral func-
tions, it however also affects the central nervous
system (CNS). The exact mechanism of action for
histamine H1-receptor antagonists still remains un-
known but the role of histamine as a neurotransmitter
has been firmly established. Histaminergic pathways
are prominent in the CNS and are related to mecha-
nisms that support alertness and vigilance (Nicholson,
1985; Qidwai et al., 2002). The sedative side effects
of H1-antagonists are caused by their affinity for the
central H1-receptors. The liposolubility of the older,
1st-generation H1-antagonists enables them to easily
cross the blood–brain barrier (Meltzer, 1990; Timmer-
man, 2000). In the 1980’s newer, 2nd-generation H1-
antagonists have been developed which possess less
side effects such as the psychomotor impairment or
sedation often found with the 1st-generation drugs
(Rombaut and Hindmarch, 1994; Vuurman et al.,
2004). These 2nd-generation drugs penetrate poorly
into the CNS and are therefore relatively non-sedating
(Bender et al., 2003; Timmerman, 2000). Also, in
contrast to the 1st-generation antihistamines, the
newer drugs have little or no affinity for muscarinic,
cholinergic, adrenergic, and serotonergic receptors
(Sangalli, 1997). This also contributes to the relative
lack of other adverse CNS or peripheral effects
reported after use of the 2nd-generation drugs (Kay,
2000). Both the pharmacodynamics and side effects
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profiles of the 2nd-generation H1-antagonists suggest
that these drugs offer a safety advantage over the 1st-
generation drugs, particularly for ambulant patients
who drive automobiles or operate other potentionally
dangerous machinery. Although these newer-generation
antihistamines were proven to be less sedative, most
still show some level of CNS impairment, particularly
at supraclinical dose levels (Casale et al., 2003;
Holgate et al., 2003; Kay, 2000; Kay and Harris, 1999;
Roberts and Gispert, 1999; Ridout and Hindmarch,
2003; Rosenzweig and Patat, 1999; Simons, 1999;
Theunissen et al., 2004; Verster et al., 2003). Reviews
of the experimental studies which have examined the
effects of H1-antagonists on performance measures
from driving simulators and on-road driving generally
have concluded that the 2nd-generation drugs pose
little or no risk to safe driving (Ogden and Moskowitz,
2004; Verster and Volkerts, 2004), although individual
adverse reactions cannot be ruled out.
More recently new drugs have been developed with
claims of being free of any sedative side effects, due to
the fact that they are incapable of crossing the
blood–brain barrier. Amongst these new-generation
antihistamines compounds are levocetirizine, fexofe-
nadine, and desloratadine (Hindmarch et al., 2001;
Ridout and Hindmarch, 2003). Although these new
drugs show little or no negative effects on psycho-
motor performance or subjective rating of sedation,
the claim that they are void of CNS effects cannot
always be held. In some cases an improvement of
psychomotor performance has been found, pointing to
possible slightly stimulating effects of these com-
pounds (Theunissen et al., 2006b; Vuurman et al.,
2004). This would imply that these compounds do
cross the blood–brain barrier or affect the CNS
through an alternative mechanism.
Rupatadine (DCI) is a new chemical entity which
possesses a potent PAF antagonist and antihistamine
activity and has been selected from a series of
N-alkylpyridine derivatives, that has demonstrated a
potent dual antihistamine and PAF antagonist activity
in animal an human models (Merlos et al., 1997).
Rupatadine is marketed in Spain in a 10mg od tablet
formulation (Izquierdo et al., 2003), and has already
been registered in several European countries and
Brazil. Rupatadine is rapidly absorbed in humans
when administered orally and extensively metabolized
in the liver, mainly by CYP3A4. Rupatadine plasma
half-life is 5.9 h. The efficacy of rupatadine for the
treatment of allergic rhinitis (both intermittent and
persistent) and chronic idiopathic urticaria has been
well established in several controlled clinical studies
(Stuebner et al., 2006). Another (Barbanoj et al., 2004)
investigated possible CNS effects of rupatadine doses
ranging between 10–80mg. Using a battery of basic
performance tests they found impairing effects of
rupatadine only at doses above 40mg, suggesting a
good balance between the clinical dose and that
producing untoward side effects. In a more recent
study (Barbanoj et al., 2006) the combined effects of
rupatadine (10 and 20mg) and alcohol (0.8 g/kg) on
cognitive performance were evaluated and compared
to the effects of alcohol combined with hydroxyzine
25mg and cetirizine 10mg. The study showed that
rupatadine 10mg in combination with alcohol did not
produce more cognitive and psychomotor impairment
than alcohol alone. In contrast, cetirizine and
hydroxyzine did significantly increase the effect of
alcohol.
Although laboratory tests and driving simulators
have often proven to be reliable and consistent in
measuring driving-related skills, their predictive
validity is only about 33% (Verster, 2002). In this
study the possible effects of rupatadine 10mg on
driving are investigated, employing a unique and
sensitive method to test drug effects on driving in real
traffic.
METHODS
Subjects
The study enrolled 22 evaluable subjects (11<, 11 ,)
through newspaper advertisements. Two subjects did
not complete the study: one moved to a different town
and one accepted job making participation impossible.
Twenty subjects (10<, 10 ,) completed the study.
Mean subject age(SD) was 27.2(3.5) years (range,
22–35 years) with a mean weight(SD) of 69.7(10.6) kg
(range, 52–92 kg) and a mean height(SD) of
176.7(8.9) cm (range, 158–192 cm). Subjects were
required to have had a driver’s license for at least
3 years prior to the study and driving experience of at
least 7500 km per year. Subjects with a history or
symptoms of severe mental or physical disorders or
substance abusewere excluded from the study, as were
subjects with active allergic rhinitis. Subjects were
screened by a medical history questionnaire and
physical examination, including a 12 lead ECG, blood
chemistry and haematology and urinary tests for drugs
of abuse. Additional exclusion criteria included
excessive smoking (>10 cigarettes per day) or
consumption of caffeinated beverages (>5 cups/
glasses per day); body weight more than 10% above
the normal average for age, sex, and height; treat-
ment with central nervous system medications or
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medications with sedative effects; and known allergic
reactions to antihistamines. Women of childbearing
potential were required to have a negative serum
pregnancy test result at screening and to use an
acceptable method of birth control before screening
and during the study. Written informed consent was
obtained from all subjects prior to participation. This
study was conducted in accordance with Good
Clinical Practice and the World Medical Association
Declaration of Helsinki (1996) and subsequent
revisions (Christie, 2000) and was approved by the
Ethics Committee of Maastricht University.
Design
The study followed a single-center, randomized,
double-blind, placebo and active-controlled, three-
way crossover design. Rupatadine (10mg), hydroxy-
zine (50mg), and placebo were administrated orally in
identical capsules once daily during treatment periods.
Treatment periods were separated by a washout period
of at least 7 days. Tests were performed between
2:00–4:30 h after dosing on each of the three test days.
Procedure
Subjects were individually trained 1 or 2 weeks prior
to their first treatment to perform the driving tests and
familiarize them with the experimental procedure.
They were required to adhere to specific procedures
prior to testing, including abstinence from alcohol or
other recreational drugs the day before testing and
retiring for sleep a minimum of 8 h prior to test days.
On each test day subjects were collected from their
homes in the morning and provided with a standard
light breakfast at the study center. Sleep quality was
measured upon arrival using the Groningen Sleep
Quality Scale (Mulder Hajonides et al., 1980) and
subjects only continued with the testing procedures if
they reported good sleep quality (Groningen score
<10) during the previous night. Additionally, subjects
were limited to one cup of tea or coffee with breakfast
on test days, and habitual smokers had to refrain from
smoking for the duration of the testing (30min before
testing and until all tests were completed). Subjects
were monitored at each visit for adverse events. At the
end of each test day subjects were returned to their
home by the experimenter.
Assessments
Highway-driving test. During the highway-driving
test (O’Hanlon et al., 1982), the subject’s task was to
operate a specially instrumented vehicle over a
distance of 100 km (61 miles) on a primary highway.
A licensed driving instructor, who could intervene if
necessary by using duplicate controls, accompanied
the subject during the test. The subject was instructed
to attempt to maintain a constant speed of 95 km (58
miles) per hour and a steady lateral position between
the delineated boundaries of the right (slower) traffic
lane. The subject was allowed to deviate from this
procedure in order to pass slower vehicles. The
vehicle’s speed and lateral position relative to the left
lane delineation were continuously recorded, sampled,
and stored on a computer system onboard. Offline
editing routines involved removal of all data segments
that revealed signal loss, disturbance, or overtaking
manoeuvres. The remaining data were used to
calculate means and standard deviations for lateral
position (SDLP) and speed (SDSP). A minimum of
75% of ‘clean’ data was required for a reliable
measurement. The primary measure was the SDLP,
which measured the continuous road tracking error.
SDLP is a very reliable characteristic of individual
driving performance: the test–retest reliability coeffi-
cient for unmedicated young and middle-aged drivers
is r¼ 0.85. It has also proven sensitive to many
sedating agents, including alcohol in blood concen-
trations as low as 0.35mg/mL [26,27]. The secondary
outcome variable was SDSP, giving an indication how
well subjects could maintain the designated speed.
Details of the highway-driving test, including power
calculations have been described fully elsewhere
(O’Hanlon and Ramaekers, 1995).
Car-following test. The car-following test (Ramae-
kers et al., 2002) involved the use of two vehicles
driving behind each other on a secondary highway for
approximately 25min. The subject controlled the
following vehicle, while the investigator controlled
the leading car. Again, a licensed driving instructor
accompanied the subject in order to intervene when
necessary. During the test the investigator in the
leading car initiated sinusoidal speed changes.
Between these maneuvers, the investigator in the
leading car randomly lit up the brake lights of his car
while the speed of the car remained constant. Subjects
were instructed to maintain a 15–30m distance to the
leading car and to react as fast as possible to the brake
lights by removing their foot from the accelerator
pedal. Standard deviation of headway (SDHW) and
brake reaction time (BRT) were the primary outcome
variables of this car-following test.
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Subjective measures. Besides administering the driv-
ing tests, the following rating scales were presented to
the subject on each test day:
- Stanford sleepiness scale. This is a well-known
questionnaire and described fully elsewhere
(Hoddes et al., 1972). The questionnaire indicates
how ‘sleepy’ people are feeling and was presented
twice on each test day: the first time prior to dosing
to register a base-line value and once after perform-
ing the driving test.
- Groningen Sleep Quality Scale (Mulder Hajonides
et al., 1980). The quality of sleep at home the night
before each trial day was assessed by means of this
questionnaire to ensure subjects were fit before they
commenced a test day.
- Subjective rating of Sedation. Both the Subject as
well as the Driving Instructor rated how ‘sedated’
the subject was during the driving test. This was
done by a 100 point VAS scale.
- Subjective rating of Driving Quality (DQ). Both the
Subject as well as the Driving Instructor rated the
quality of the subject’s driving. This was done by a
100-point VAS scale.
Statistical analysis. Sample size was based upon a
power calculation of the primary outcome variable in
the driving test, SDLP. With a sample size of 20
subjects, an a level of 0.05 (two-tailed), differences
of 0.65 standardized units were detectable with a
power of 85% (O’Hanlon and Ramaekers, 1995). Data
analysis was performed employing the GLM routines
from the SPSS statistical program series (Version 13,
Norusis, 2004) on Windows-XP microcomputer. Effi-
cacy variables were analyzed with an analysis of
variance model (ANOVA) for crossover designs with
terms for treatment, phase, and subject effects. Pair-
wise comparisons were performed using the least
square means from the model. The active control
group (hydroxyzine) was included for reference pur-
poses. Since the study was oriented towards safety, a
significance level of a¼ 0.05 was used in all statistical
tests to detect differences between treatment
responses.
RESULTS
Missing data
Due to a technical error the data of subject #17 are
incomplete for the hydroxyzine condition. The follow-
ing analyses were therefore based on a dataset of
19 subjects in stead of the full 20 subjects: car-
following test (BRT and SDHW; Subjective scales:
Stanford sleepiness scale (STANFORD) and Driving
Quality rating by the subject (DQ-S).
Standard deviation of lateral position (SDLP)
Figure 1 shows the mean SDLP (#SEM) for each of
the three treatment conditions. The means of the
rupatadine and placebo conditions were comparable
(18.64 and 18.81 cm, respectively) and the SDLP in
the hydroxyzine condition was much higher than the
other two (23.35 cm). The higher SDLP indicated
worse driving. ANOVA showed a significant overall
effect of Treatment (F2,36¼ 21.57; p< 0.001). Sub-
sequent paired comparisons showed significant inc-
rease in SDLP after hydroxyzine treatment compared
to both rupatadine (F1,36¼ 33.43; p< 0.001) and
placebo (F1,36¼ 25.57; p< 0.001). There was no
difference in SDLP between the rupatadine and
placebo group (F1,36¼ 0.04; p¼ 0.848). No effect
of period was found, indicating a lack of learning or
habituation to the driving test procedure.
Standard deviation of speed (SDSP)
The mean (#SEM) scores of the secondary outcome
variable on the highway-driving test, SDSP are shown
in Figure 2. Twenty evaluable data sets were available
for the analysis. Subjects were instructed to maintain a
steady speed at all times and the deviation from
the mean speed was comparable for the rupatadine
and placebo conditions. In the hydroxyzine condi-
tion subjects showed a larger variation in speed
difference during the test. Overall ANOVA showed
this to be highly significant (F2,36¼ 17.04; p< 0.001).
Standard Deviation Lateral Position (SDLP)
Mean (± SEM)
14
16
18
20
22
24
26
28
HydroxyzinePlaceboRupatadine
Drug Condition
 
[ c
m 
]
Figure 1. Mean (# SEM) standard deviation of lateral position
(SDLP) scores for each treatment condition (rupatadine 10mg,
placebo, hydroxyzine 50mg; N¼ 20)
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Subsequent pairwise comparisons showed that after
treatment with hydroxyzine, subjects significantly
varied in speed more compared to both rupatadine
(F1,36¼ 21.75; p< 0.001) as well as placebo
(F1,36¼ 28.87; p< 0.001) conditions. Scores in the
rupatadine group were not different from scores in the
placebo group (F1,36¼ 0.50; p¼ 0.482). There was no
effect of period on this variable, indicating subjects
did not improve or degrade in time over the study.
Standard deviation of headway (SDHW)
The SDHW provides information on how ‘well’
subject keep an equal distance to the car in front of
them. Figure 3 shows the means (#SEM) for all treat-
ment conditions. The mean values for all conditions
were similar and ANOVA revealed no effect of Treat-
ment on SDHW (F2,35¼ 0.67; p< 0.517). Pairwise
comparisons showed no differences between means of
either rupatadine and hydroxyzine (F1,35¼ 0.97; p<
0.333), hydroxyzine and placebo (F1,35¼ 0.01; p<
0.986), or rupatadine and placebo (F1,35¼ 1.04;
p< 0.315). A small positive, but significant effect
was found for period (F2,35¼ 3.84; p¼ 0.031),
indicating a slight learning effect over the study.
Brake reaction time (BRT)
Figure 4 shows mean (#SEM) scores for the three
treatment conditions. A higher score implied that
subjects were slower to respond to the brake signal
presented. The mean BRT was slightly lower for the
rupatadine condition compared to both placebo and
hydroxyzine. ANOVA did not show an overall
treatment effect (F2,35¼ 1.59; p< 0.218) and pairwise
comparisons did not show an effect between either
rupatadine and hydroxyzine (F1,35¼ 2.41; p< 0.130),
hydroxyzine and placebo (F1,35¼ 0.01; p< 0.957), or
between rupatadine and placebo (F1,35¼ 2.34;
p< 0.135). There was no effect of period on this
variable, indicating subjects did not improve or
degrade in time over the study.
Stanford sleepiness scale (STANFORD)
The Stanford sleepiness scale was administered twice
on each of the three treatment days: the first time
predosing as a baseline value and the second time after
concluding the Driving tests. Figure 5 shows
differences in Mean Compound Scores, a higher
score indicating an increase in subjective sleepiness.
Mean scores for the hydroxyzine treatment condition
Standard Deviation Speed (SDSP)
Mean (± SEM)
1.0
1.2
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Figure 2. Mean (# SEM) standard deviation of speed (SDSP)
scores for each treatment condition (rupatadine 10mg, placebo,
hydroxyzine 50mg; N¼ 20)
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Figure 3. Mean (# SEM) brake reaction time (BRT) scores for
each treatment condition (rupatadine 10mg, placebo, hydroxyzine
50mg; N¼ 19)
Standard Deviation Headway
Mean (± SEM)
2.00
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3.00
3.50
4.00
HydroxyzinePlaceboRupatadine
Drug Condition
 
[ m
 ]
Figure 4. Mean (# SEM) standard deviation of headway (SDHW)
scores for each treatment condition (rupatadine 10mg, placebo,
hydroxyzine 50mg; N¼ 19)
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were about twice as high compared to both the rupa-
tadine and placebo treatment condition, and a signi-
ficant overall effect for treatment was found (F2,35¼
12.89; p< 0.001). Pairwise comparisons showed that
both the mean differences between rupatadine and
hydroxyzine as well as placebo and hydroxyzine were
significantly different (F1,35¼ 18.63; p< 0.001 and
F1,35¼ 20.48; p< 0.001, respectively). The small
difference between the placebo and rupatadine groups
was not significant (F1,35¼ 0.04; p< 0.840). No effect
of period was found on this variable.
Driving Quality scale (subject and instructor)
Both the instructor as well as the subject rated how
well the subject had performed in the driving test and
rated this as the DQ on a Visual Analogue Scale
running from 0–100. The higher the score the better
the driving is rated.
Mean Subject rated Driving Quality (DQ-S) and
Instructor rated Driving Quality (DQ-I) are shown in
Figure 6 .The best mean score for DQ-S was seen in
the rupatadine treatment condition, with a slightly
lower rating for the placebo treatment condition. The
scores in the hydroxyzine were almost 33% lower
compared to the rupatadine group, indicating a large
difference in rating. ANOVA showed a highly signi-
ficant effect of treatment (F2,35¼ 23.73; p< 0.001)
with likewise significant effect for differences
between rupatadine and hydroxyzine (F1,35¼ 42.20;
p< 0.001) and the difference between placebo and
hydroxyzine (F1,35¼ 28.44; p< 0.001). Mean scores
of the rupatadine group did not differ from placebo
(F1,35¼ 1.44; p< 0.239).
The mean scores for DQ-I resembled those for
DQ-S. Again the score is lowest in the hydroxyzine
group; although the absolute differences are smaller,
like the standard error. An overall treatment effect is
found (F2,36¼ 4.72; p< 0.015); with the hydroxyzine
group rating worse compared to rupatadine (F1,36¼
5.75; p< 0.022) and placebo (F1,36¼ 8.20; p< 0.007).
No difference was found between the rupatadine and
placebo groups (F1,36¼ 0.22; p< 0.644). No effect for
eriod was found for the DQ-S and DQ-I variables.
Perceived Sedation was recorded by presenting the
subject and the instructor with a VAS rating scale
directly after completing the Driving Test. Figure 7
shows the means of the Instructor rated Sedation
(SED-I) and Subject rated Sedation (SED-S), indi-
cating howmuch they judged the subject to be sedated.
Stanford Sleepiness Scale
Mean difference from baseline (± SEM)
0
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2
3
HydroxyzinePlaceboRupatadine
Drug Condition
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 ]
Figure 5. Mean (# SEM) difference scores on the Stanford scale
for each treatment condition (rupatadine 10mg, placebo, hydroxy-
zine 50mg; N¼ 20)
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Figure 6. Mean (# SEM) rating of Driving Quality for each
treatment condition (rupatadine 10mg, placebo, hydroxyzine
50mg; N¼ 20 for instructor rated sedation and N¼ 19 for subject
sedated rating)
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Figure 7. Mean (# SEM) rating of sedation for each treatment
condition (rupatadine 10mg, placebo, hydroxyzine 50mg; N¼ 20
for instructor rated sedation and N¼ 19 for subject sedated rating)
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The results for SED-I showed an overall treatment but
SED-S did not (F2,36¼ 12.56; p< 0.001 and F2,36¼
0.25; p< 0.782, respectively). Paired comparisons
only showed effects on SED-I, with hydroxyzine rated
more sedative compared to both rupatadine as well as
Placebo (F1,36¼ 17.40; p< 0.001 and F1,36¼ 20.19;
p< 0.001, respectively).
Safety
A total of 16 adverse effects (AE) were reported for all
22 subjects that enrolled in the study. Most frequently
‘tiredness’ (5 reports) and ‘drowsiness/sleepiness’
(4 reports). Adverse events were reported after hydroxy-
zine (7 reports), rupatadine (3 reports), placebo
(3 reports), and prior to dosing (1 report). Most reports
of AE were expected and did not pose any serious
safety hazard to the subjects’ health. All AE’s were
resolved within 24 h after onset. In seven experimental
procedures the actual driving was terminated for
safety reasons. This meant that the Driving Instructor
observed that the subject was getting too sedated or
sleepy to continue safely and terminated the test. In
two cases this was after treatment with rupatadine and
in five cases after hydroxyzine. This is commonly seen
in this test and has been documented in over 60 studies
with other drugs affecting psychomotor behavior,
especially after the subject has been driving over
40min and vigilance effects become predominant
(O’Hanlon and Ramaekers, 1995). In all cases enough
data from the driving tests were available (>75%) to
use the data for analysis.
DISCUSSION
Findings from the highway-driving test confirm the
absence of drug-induced impairment in subjects who
received rupatadine, with almost identical SDLP
scores as placebo treated subjects. In contrast, the
SDLP score in the hydroxyzine condition was
significantly higher (4.54 cm) and relevant, having
an impairing effect comparable to a Blood Alcohol
concentration of 0.9% (Brookhuis, 1998). The results
of the car-following test were less conclusive. In the
hydroxyzine condition the BRT was not slower
compared to the placebo condition. Also no effect
for hydroxyzine was found on the SDHW. No
straightforward explanation for this finding can be
given. In previous studies with the same test the
positive control condition did show effects (Ramae-
kers et al., 2002; Vuurman et al., 2004). Nonetheless
there was also no impairment in the rupatadine
treatment condition. Results of the subjective scales
and questionnaires support the findings of the driving
tests. Rupatadine showed no effect on driving perfor-
mance related scales in contrast with the sedating
effect of hydroxyzine on both the Stanford sleepiness
scale and the rating of DQ. An interesting finding was
the large difference in rating of sedation between the
instructor and the subject in the hydroxyzine
condition. The instructor clearly rated the sedation
to be much worse than the subject. Judging from the
performance data the subjects underrated their
sedation in the hydroxyzine condition.
The effects of other 2nd-generation antihistamines
have also been investigated in studies that utilized
similar driving and psychomotor performance test
methodology (Brookhuis, 1998; O’Hanlon and
Ramaekers, 1995). Overall, the results of these studies
demonstrated that driving and psychomotor perform-
ance impairment varies between 1st- and
2nd-generation antihistamines and possibly among
such 2nd-generation agents as loratadine and cetir-
izine as well. Previous studies (Theunissen et al.,
2006a; Vermeeren and O’Hanlon, 1998; Vuurman
et al., 2004; Vuurman et al., 1994; Theunissen et al.,
2006a) show that treatment with the recommended
therapeutic dose of 2nd-generation antihistamines
such as mizolastine ebastine, desloratatadine, mequi-
tazine, or fexofenadine results in mean SDLP values
comparable with placebo. However, sedation or
somnolence are also reported in trials with new
antihistamines such as levocetirizine (Bachert et al.,
2004). Driving studies with the recommended
therapeutic dose of cetirizine are less straightforward
and show either moderate impairment (Ramaekers
et al., 1992) or lack of impairment (Volkerts and van
Laar, 1995). However, most antihistamines affect
driving performance when given at twice the
recommended therapeutic dose. The effect seems to
be beneficial with fexofenadine; (Vermeeren and
O’Hanlon, 1998) in contrast, cetirizine and loratadine
cause a less favorable sedative effect. The differential
effects on driving performance suggest the
2nd-generation antihistamines may have different
mechanisms of action. As for the compound under
investigation in this study, Barbanoj et al. (2004)
showed a dose dependent relation of higher doses of
rupatadine with reported sedation, although psycho-
motor impairment on the used tests is only seen after a
80mg dose of rupatadine. This does however support
the notion that rupatadine has some CNS effects at
higher doses too. The effects are however only
apparent at doses well above those administered
clinically, giving the drug a largemargin of safety. One
noteworthy finding was the large difference between
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subject rated quality of driving and sedation on one
hand (Figures 6 and 7) and instructor rated quality of
driving and sedation on the other hand in the
hydroxyzine condition. This suggests that subjects
taking this older antihistamine underrated the effects
of the drug.
Most discussions on sedative effects of different
classes of antihistamines ascribe differences in the
sedative potentials to receptor occupancy, receptor
selectivity, and brain penetration (Handley and Graff,
1998; Simons, 1994). The inability to penetrate the
blood–brain barrier has been put forward as the major
advantage of 2nd- and the new-generation antihista-
mines over the older ones (Hindmarch and Shamsi,
1999). Recently, both animal and in-vitro studies
suggest a more complex system regulation of the brain
distribution of antihistamine drugs (Chen et al., 2003;
Devillier, 2006; Mahar Doan et al., 2004). In these
studies the role of the P-glycoprotein (Pgp) efflux
system and plasma protein binding have been
described for a large number of antihistamines. The
authors provide theoretical pharmacokinetic proper-
ties that antihistamines should possess to limit its CNS
activity. Combining these insights with efficacy data
and side effect, profiles should ultimately lead to a
better understanding of the mechanism of action on
the CNS and will provide a sounder scientific basis
than dose ranging studies alone.
In this study rupatadine was well tolerated. Three
subjects reported AE’s while receiving rupatadine and
two subjects did not complete the driving test,
compared to the hydroxyzine group where five driving
tests were not completed. In conclusion we can state
that rupatadine, given at 10mg, does not impair actual
driving performance, is well tolerated, and compar-
able with the more recent antihistamines compounds.
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